Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Antisense oligonucleotide treatment of Ataxia-Telangiectasia IND#144349 IND/IDE April 19, 2024

Award Number: R01FD008498
ORGANIZATION: FOOD AND DRUG ADMINISTRATION
OPDIV: FDA
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/25/2025
PERIOD OF PERFORMANCE END DATE: 08/31/2029

Group Awards By:

View Award Description

Antisense oligonucleotide treatment of Ataxia-Telangiectasia IND#144349 IND/IDE April 19, 2024 - ABSTRACT A-T is a pediatric neurodegenerative condition caused by recessive mutations in ATM, a gene which encodes a critical element of the cellular DNA damage response. Individuals with A-T suffer from gradual loss of muscle coordination due to progressive cerebellar degeneration, leading to loss of ability to swallow, read, communicate, and ambulate. There are currently no known effective treatments for this severely debilitating condition, and it is typically fatal by young adulthood. Here we study the safety and effectiveness of a novel genetic treatment strategy for ataxia telangiectasia (A-T). Antisense oligonucleotides are 15-25 nucleotide snippets of synthetic RNA-like molecules that distribute broadly in the brain and spinal cord when administered via intrathecal injection. They bind to specific genomic targets via Watson-Crick basepairing, and can be designed to change patterns of gene splicing in therapeutically useful ways. 15% of individuals with A-T have mutations that could be treatable using splice-modulating ASOs. Here, we test the clinical therapeutic utility of atipeksen, a 22 nucleotide ASO designed to correct the impact of ATM c.7865C>T, a recurrent mutation that causes disease by creating an abnormal splice site in ATM exon 53. Atipeksen treatment of cell lines from A-T patients bearing this mutation inhibits use of this abnormal splice site, restoring normal ATM splicing and rescuing normal gene function. The current clinical trial is designed to test the safety and effectiveness of atipeksen in A-T in individuals bearing the ATM c.7865C>T mutation. The goal of this study is to slow A-T associated neurodegeneration, delay the progression of neurologic symptoms of A-T, and improve quality of life, using neurologic disability rating scales, brain imaging, and exploratory biomarkers as outcomes. Results from treated patients will be compared against a control cohort of untreated A-T patients with ATM c.7865C>T. Success will provide an empirical foundation for advancing additional precision genetic therapies for A-T and other neurodegenerative conditions.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = $0 )
2026	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	11/20/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2025 ( Subtotal = $3,577,616 )
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	000	1	9/22/2025	NEW	$893,520
2025	2025	CHILDREN'S HOSPITAL CORPORATION, THE	300 LONGWOOD AVE	BOSTON	MA	02115	SUFFOLK	USA	Food and Drug Administration Research	001	1	9/30/2025	NEW	$2,684,096
														Subtotal = $3,577,616

Grand Total All Awards = $3,577,616

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Antisense oligonucleotide treatment of Ataxia-Telangiectasia IND#144349 IND/IDE April 19, 2024

Award Number: R01FD008498

ORGANIZATION: FOOD AND DRUG ADMINISTRATION

OPDIV: FDA

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/25/2025

PERIOD OF PERFORMANCE END DATE: 08/31/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer